LncRNA MEG3 rs3087918 was associated with a decreased breast cancer risk in a Chinese population: a case-control study

Yi Zheng
Xi'an Jiaotong University Second Affiliated Hospital
Meng Wang
Xi'an Jiaotong University Second Affiliated Hospital
Shuqian Wang
Zhejiang University School of Medicine First Affiliated Hospital
Peng Xu
Xi'an Jiaotong University Second Affiliated Hospital
Yujiao Deng
Xi'an Jiaotong University Second Affiliated Hospital
Shuai Lin
Xi'an Jiaotong University Second Affiliated Hospital
Na Li
Xi'an Jiaotong University Second Affiliated Hospital
Kang Liu
Xi'an Jiaotong University Second Affiliated Hospital
Yuyao Zhu
Xi'an Jiaotong University Second Affiliated Hospital
Zhen Zhai
Xi'an Jiaotong University Second Affiliated Hospital
Ying Wu
Xi'an Jiaotong University Second Affiliated Hospital
Zhi-Jun Dai (✉ dzj0911@126.com)
https://orcid.org/0000-0001-5209-8626
Gaixia Zhu
Xi'an Jiaotong University Second Affiliated Hospital

Research article

Keywords: MEG3; SNP; breast cancer; case-control study; miRNA.

Posted Date: July 7th, 2020

DOI: https://doi.org/10.21203/rs.2.22717/v3

Version of Record: A version of this preprint was published on July 15th, 2020. See the published version at https://doi.org/10.1186/s12885-020-07145-0.

Abstract

Background: LncRNA MEG3 expressed abnormally in various cancers including breast cancer, but no studies reported the correlation between MEG3 SNPs and breast cancer susceptibility among Chinese women.

Methods: This study is aimed to explore the association between three SNPs of MEG3 (rs3087918, rs7158663, rs11160608) and breast cancer. The study is a population-based case-control study including 434 breast cancer patients and 700 healthy controls. Genotyping was performed using Sequenom MassArray technique. Function prediction of rs3087918 were based on RNAfold and lncRNASNP2 databases.

Results: Pooled analysis indicated that rs3087918 was related to a decreased risk of breast cancer [GG vs. TT: OR(95%) = 0.67(0.45-0.99), *P* = 0.042; GG vs. TT + TG: OR(95%) = 0.69(0.48-0.99), *P* = 0.046], especially for women aged <=49 [GG vs. TT: OR(95%) = 0.40(0.22-0.73), *P* = 0.02]. Comparison between case groups showed genotype GG and TG/GG of rs3087918 were associated with her-2 receptor expression [GG vs. TT: OR(95%) = 2.37(1.24-4.63), *P* = 0.010; TG + GG vs. TT: OR(95%) = 1.50(1.01-2.24), *P* = 0.045]. We didn't find statistical significance for rs11160608, rs7158663 and breast cancer. Structure prediction based on RNAfold found rs3087918 may influence the secondary structure of MEG3. The results based on lncRNASNP2 indicated that rs3087918 may gain the targets of hsa-miR-1203 to MEG3, while loss the target of hsa-miR-139-3p and hsa-miR-5091 to MEG3.

Conclusions: MEG3 rs3087918 was associated with a decreased risk of breast cancer. MEG3 haplotype TCG may increase the risk of breast cancer.

Background

Breast cancer (BC) is a serious threat to women's health. According to American *cancer statistics 2020* [1], there will be an estimated 276,480 new BC cases and 42,170 BC related death in 2020. For females, BC is the most common diagnosed cancer (24.2% of the total cases) and the leading cause of cancer death (15.0% of the total cancer death). Although epidemiological studies have identified several risk factors involved in BC, such as age, hormonal state, and family history[2], the pathogenesis of BC is still unclear. BC is a complex and genetically heterogeneous disease in which genetic changes such as abnormal amplification of oncogenes, or deletion/mutation of tumor suppressor genes, play a substantial role [3-5].

Maternally expressed gene 3 (MEG3) is an imprinted gene located at chromosome 14q32.3 in humans, encoding a long non-coding RNA (lncRNA) belonging to the imprinted DLK1-MEG3 regions [6]. This region contains at least three paternally expressed protein coding genes and numerous maternally expressed noncoding RNAs [7]. The imprinted expression of these genes was related to cell development and growth [8], and experiments in vitro indicated MEG3 can suppress the proliferation of human cancer cells lines [9]. Researchers found loss of MEG3 related to a variety of human cancers, such as gastric [10], cervical

[11], and breast [12] cancer. MEG3 can inhibit the occurrence of tumor through various aspects. Firstly, MEG3 can inhibit the proliferation of tumor cells and consequently induce apoptosis, which has been confirmed by in vitro experiments and animal models [13]. Secondly, MEG3 plays a role in epigenetic regulation and can alter the function of cancer cells by affecting DNA methylation and regulating the functions of snoRNA and miRNA [14, 15]. Moreover, MEG3 is involved in the regulation of many tumor-related signaling pathways, including p53, MDM2, and pRb pathway [16].

Single-nucleotide polymorphism (SNP) mainly refers to the DNA sequence polymorphism caused by the variation of a single nucleotide at the genome level. It is the most common genetic variant in the human genome, accounting for 90% of all known polymorphisms [17]. To date, Genome Wide Association Study (GWAS) and multiple large-scale sequencing have identified many SNPs in more than 70 genes associated with breast cancer [18, 19]. SNP has been considered a potential biomarker of genetic background to predict risk, progression, and treatment response to various diseases. Previous investigation indicated that several SNPs in MEG3 genes are associated with breast cancer susceptibility [20]. However, there are no investigation to explore the relationship between MEG3 polymorphisms and breast cancer among Chinese women. In this study, we genotyped three polymorphisms (rs3087918, rs11160608 rs7158663) in MEG3 gene based on 434 BC patients and 700 healthy controls, to explore their relationship with breast cancer.

Methods

Study subjects

In total, 1134 females were recruited for this population-based case-control study. Among these, 434 breast cancers were enrolled in the Department of Oncology, the Second Affiliated Hospital, Xi'an Jiaotong University, from 2013 to 2015. 700 healthy females were randomly recruited from medical center of the same hospital during the same period. All BC patients were diagnosed by pathology and detailed immunohistochemical analysis. BC patients who had a history of other malignant diseases or receiving chemotherapy or radiotherapy were excluded. The controls were matched to cases by age (±2 years) and had no history of malignant tumors, no history of chemoradiotherapy, no obvious abnormality in blood routine examination. The protocol of this study was approved by the Ethics Committee of the Second Affiliated Hospital of Xi'an Jiaotong University Shaanxi Province (Xi'an, China). All patients gave written informed consent prior to participation in the study.

SNP selection and Genotyping

SNPs were selected from NCBI dbSNP database (https://www.ncbi.nlm.nih.gov/projects/SNP) and relevant literature [20-22] according to the following criteria. First, the minor allele frequency (MAF) was no less than 0.05 among Chinese population. Secondly, the SNPs located in the 5'- flanking region, 5' untranslated region, 3' untranslated region, and exon of MEG3 gene. We finally chose three MEG3 SNPs rs3087918, rs11160608 rs7158663 to study. Peripheral blood samples were collected in EDTA-coated tubes and conserved at -80℃. Genome DNA were extracted from whole blood samples using ComWin

BloodGen Mini Kit (QIAGEN, China, Beijing). Ultraviolet spectrophotometer (Nanodrop, Thermo Scientific, Waltham, MA) was utilized to measure the purity and concentration of extracted DNA. We designed multiplexed SNP MassEXTEND assay using Sequenom MassARRAY Assay Design 3.0 software. DNA samples were genotyped by Sequenom MassARRAY RS1000 according to the standard protocol. The primers applied for the three SNPs were shown in *Supplemental table S1*.

Statistical analysis

The HWE of the three SNPs were calculated using Fisher's exact test in controls group. Student's t test was adopted to evaluated the difference of age distribution and body mass index (BMI) between BC patients and healthy controls. Two-sided Pearson's chi-square tests were applied to access the differences in the categorical variables between cases and controls, such as age (<=49 and >49), BMI, menstrual-status, and allelic frequencies. $P < 0.05$ was considered statistically significant. We also calculated odds ratios (ORs) and 95% confidence intervals (CIs) using logistic regression analysis. Haplotype analysis were conducted by Haploview 4.2. Other statistical analyses were performed using the version R 3.5.2 software.

Function prediction based on databases

We used RNAfold (http://rna.tbi.univie.ac.at//cgi-bin/RNAWebSuite/RNAfold.cgi) and LncRNASNP2 (http://bioinfo.life.hust.edu.cn/lncRNASNP/) database to predict the effect of SNP on MEG3. RNAfold is a classic database to predict RNAs structure. Free energy represents the amount of energy that needs to be injected to change the structure. The smaller the corresponding value is, the more stable the structure will be. LncRNASNP2 is a novel database containing 7260238 SNPs on 141353 human lncRNA transcripts and 3921448 SNPs on 117405 mouse lncRNA transcripts [23]. We used this database to predict the potential function of the MEG3 polymorphisms.

Results

Demographical and clinical information of study population

This study contained 434 BC cases and 700 healthy control. All the subjects were Han Chinses women from northwest China. There were no statistically significant differences in age distribution, BMI and menopausal status between the patients and the control group. The detail demographical and clinical information was display in *Table 1*. BMI was a statistical index to estimate the body fat in people of any age. In this study, BMI was divided into four levels (underweight, normal weight, overweight, and obese) based on Chinese reference standard.

Table 1 Demographic information.

Characteristics		Cases (%)	Controls (%)	P value
Number		434	700	
Age (mean ± SD)		51.95±10.35	51.83±17.28	0.879[a]
≦49		180(41.5)	298(42.6)	
49		254(58.5)	402(57.4)	0.716
BMI, kg/m2 (mean ± SD)		22.38±2.61	22.71±4.00	0.084[a]
Menopausal status				
Premenopausal		157(36.2)	188(41.8)	
Postmenopausal		277(63.8)	262(58.2)	0.506
TNM Stage				
		114(26.3)	-	-
		192(44.2)		-
		1. -		
		89(20.5)	-	-
		39(9)	-	-
Immunohistochemistry results				
ER	–	142(32.7)	-	-
	+	292(67.3)	-	-
PR	–	189(43.5)	-	-
	+	245(56.5)	-	-
Her-2	–	250(57.6)	-	-
	+	184(42.4)	-	-

[a] Student's t-test

BMI: body mass index; ER: estrogen receptor; PR: progesterone receptor; Her-2: human epidermal growth factor receptor-2.

The associations between *MEG3* SNPs and BC risk

Three SNP in MEG3 gene (rs3087918, rs11160608 rs7158663) were genotyped in all recruited subjects, and their detected rate were 99.1%, 99.2% and 99.4%, respectively. The genotype distribution of the three polymorphisms in control groups accorded with HWE (rs11160608: P_{HWE} = 0.844; rs3087918: P_{HWE} = 0.968; rs7158663: P_{HWE} = 0.334). We didn't find statistical significance for rs11160608, rs7158663 and breast cancer (P > 0.05 in all genetic models). Pooled analysis indicated that rs3087918 was related to a decreased risk of breast cancer [GG vs. TT: OR (95%CI) = 0.67(0.45-0.99), P = 0.042; GG vs. TT + TG: OR (95% CI) = 0.69(0.48-0.99), P = 0.046]. The detail results were showed in *Table 2*.

Table 2 Association between MEG3 gene polymorphisms and risk of breast cancer (rs11160608, rs3087918, rs7158663)

SNPs genetic model	Genotype	Cases (%) N=434	Controls (%) N=700	OR (95%CI)	*P* value
rs11160608					
Co-dominant	AA	126(29.7)	227(32.4)	reference	
	AC	218(51.4)	341(48.7)	1.15(0.87-1.52)	0.316
	CC	80(18.9)	132(18.9)	1.09(0.77-1.55)	0.625
Dominant	AA	126(29.7)	227(32.4)	reference	
	AC+CC	298(70.3)	473(67.6)	1.14(0.87-1.48)	0.342
Recessive	AA+AC	344(81.1)	568(81.1)	reference	
	CC	80(18.9)	132(18.9)	1.00(0.74-1.36)	0.996
Allele	A	470(55.4)	795(56.8)	reference	
	C	378(44.6)	605(43.2)	1.06(0.89-1.26)	0.528
rs3087918					
Co-dominant	TT	171(40.2)	259(37.0)	reference	
	TG	207(48.7)	334(47.7)	0.94(0.72-1.22)	0.633
	GG	47(11.1)	107(15.3)	0.67(0.45-0.99)	0.042*
Dominate	TT	171(40.2)	259(37.0)	reference	
	TG+GG	254(59.8)	441(63.0)	0.87(0.68-1.12)	0.279
Recessive	TT+TG	378(88.9)	593(84.7)	reference	
	GG	47(11.1)	107(15.3)	0.69(0.48-0.99)	0.046*
Allele	T	549(64.6)	852(60.9)	reference	
	G	301(35.4)	548(39.1)	0.85(0.71-1.02)	0.077
rs7158663					
Co-dominate	GG	224(52.5)	403(0.6)	reference	
	GA	170(39.8)	250(0.4)	1.22(0.95-1.58)	0.12
	AA	33(7.7)	47(0.1)	1.26(0.79-2.03)	0.333
Dominate	GG	224(52.5)	403(0.6)	reference	
	GA+AA	203(47.5)	297(0.4)	1.23(0.97-1.57)	0.094
Recessive	GG+GA	394(92.3)	653(0.9)	reference	
	AA	33(7.7)	47(0.1)	1.16(0.73-1.85)	0.52
Allele	G	618(72.4)	1056(75.4)	reference	
	A	236(27.6)	344(24.6)	1.17(0.97-1.42)	0.107

*The *P* Value < 0.05.

OR: odds ratio; CI: confidence interval.

Stratified Analysis by age, BMI and menopausal status

Then, we conducted stratified analysis based on age, BMI and menopausal status to further explore their effect on relationship between BC susceptibility and the three SNPs in MEG3. BMI was divided into two levels (BMI < 24 kg/m^2 and BMI >= 24 kg/m^2). No association was found between rs11160608, rs7158663 and breast cancer when stratified by age, BMI and menopausal status (*Supplemental Table S2*). Rs3087918 was related to a reduced susceptibility for women aged <=49 [GG vs. TT: OR(95%CI) = 0.40(0.22-0.73), *P* = 0.02] (*Table 3*).

Table 3. Stratified Analysis of rs3087918 by age, BMI and menopausal status.

Group	rs3087918 (Case/Control)			
	TT	TG	GG	TG+GG
Age				
<=49	69/93	87/141	19/64	106/205
OR(95%CI)	1.00 (reference)	0.83(0.55-1.25)	0.40(0.22-0.73)	0.70(0.47-1.03)
P-value		0.378	0.002*	0.069
> 49	102/166	120/193	28/43	148/236
OR(95%CI)	1.00 (reference)	1.01(0.72-1.42)	1.06(0.62-1.81)	1.02(0.74-1.41)
P-value		0.945	0.832	0.901
BMI(kg/m2)				
<24	134/206	147/254	35/74	182/328
OR(95%CI)	1.00 (reference)	0.89(0.66-1.20)	0.73(0.46-1.15)	0.85(0.64-1.13)
P-value		0.441	0.171	0.271
>=24	37/53	60/80	12/33	72/113
OR(95%CI)	1.00 (reference)	1.07(0.63-1.84)	0.52(0.24-1.14)	0.91(0.55-1.53)
P-value		0.794	0.100	0.727
Menstrual-status				
postmenopausal	114/167	128/201	29/65	157/266
OR(95%CI)	1.00 (reference)	0.93(0.67-1.29)	0.65(0.40-1.08)	0.87(0.64-1.18)
P-value		0.675	0.093	0.356
menstruating	57/92	79/133	18/42	97/175
OR(95%CI)	1.00 (reference)	0.96(0.62-1.48)	0.69(0.36-1.32)	0.90(0.59-1.35)
P-value		0.848	0.260	0.597

*The P Value < 0.05.

BMI: body mass index; OR: odds ratio; CI: confidence interval.

Relationship between MEG3 rs3087918 and clinical characteristics of BC

To further explore the effect of rs3087918 loci and clinicopathological information on BC susceptibility, correlation analysis was conducted in the cases group defined by age, BMI, menopausal status, tumor size, metastasis, clinical stage, ER/PR status and Her-2. As showed in *Table 4*, there is a significant association of the GG genotype with tumor size according to the 95%CI (1.01-3.92), while the *P* value of tumor size is 0.05. In this study, $P < 0.05$ was considered statistically significant. Thus, we considered there was no association found between GG genotype of rs3087918 and tumor size. This is a controversial result that needs further study to clarify. GG and TG+GG genotypes were associated with the over-expression of Her-2 [GG vs. TT: OR(95%CI) = 2.37(1.24-4.63), $P = 0.010$; TG + GG vs. TT: OR(95%CI) = 1.50(1.01-2.24), $P = 0.045$]. We further divided the cases into luminal, Her-2 and triple negative breast cancer (TNBC) groups according to molecular classification. However, we found no association between three SNPs of MEG3 and the different molecular typing states of BC (*Supplemental Table S3*).

Table 4. Relationship between MEG3 rs3087918 and clinical characteristics of cases.

rs3087918	TT	TG	GG	TG+GG
Age				
>49/<=49	102/69	120/87	28/19	148/106
OR(95%CI)	1.00 (reference)	0.93(0.62-1.408)	1.00(0.52-1.95)	0.94(0.64-1.40)
P-value		0.742	0.993	0.777
BMI(kg/m^2)				
>=24/<24	37/134	60/147	12/35	72/182
OR(95%CI)	1.00 (reference)	1.48(0.92-2.37)	1.24(0.59-2.63)	1.43(0.91-2.26)
P-value		0.104	0.571	0.120
Menstrual status				
yes/no	114/57	128/79	29/18	157/97
OR(95%CI)	1.00 (reference)	0.81(0.53-1.24)	0.81(0.42-1.59)	0.81(0.54-1.21)
P-value		0.330	0.526	0.307
Tumor size(cm)				
>2/<=2	85/86	107/100	31/16	138/116
OR(95%CI)	1.00 (reference)	1.08(0.72-1.62)	1.96(1.01-3.92)	1.20(0.82-1.73)
P-value		0.701	0.050	0.350
Metastasis				
Positive/negtive	93/78	104/103	24/23	128/126
OR(95%CI)	1.00 (reference)	0.85(0.56-1.27)	0.88(0.46-1.68)	0.85(0.58-1.26)
P-value		0.422	0.686	0.419
Clinical Stage				
III-IV/I-II	51/120	59/148	16/31	75/179
OR(95%CI)	1.00 (reference)	0.94(0.60-1.47)	1.21(0.60-2.39)	0.99(0.65-1.51)
P-value		0.778	0.579	0.948
ER				
Positive/negtive	115/56	138/69	33/14	171/83
OR(95%CI)	1.00 (reference)	0.97(0.63-1.50)	1.15(0.58-2.37)	1.00(0.66-1.51)
P-value		0.904	0.700	0.988
PR				
Positive/negtive	94/77	112/95	33/14	145/109
OR(95%CI)	1.00 (reference)	0.97(0.64-1.45)	1.93(0.98-3.97)	1.09(0.74-1.61)
P-value		0.867	0.063	0.666
Her-2				
Positive/negtive	62/109	90/117	27/20	117/137
OR(95%CI)	1.00 (reference)	1.35(0.89-2.05)	2.37(1.24-4.63)	1.50(1.01-2.24)
P-value		0.155	0.01*	0.045*

*The P Value < 0.05.

BMI: body mass index; ER: estrogen receptor; PR: progesterone receptor; Her-2: human epidermal growth factor receptor-2; OR: odds ratio; CI: confidence interval.

Haplotype analysis of MEG3 SNPs and associations with the risk of BC

To explore the combined effect the three SNPs in MEG3, we performed haplotype analysis by Haploview. The results of the haploid analysis indicated that TCG haplotype may increase the risk of breast cancer compared with the wild haplotype TAG [OR (95%CI) = 2.97(1.66-5.31), $P < 0.001$]. Other haplotypes

showed no association with BC (*Table 5*). The order of the three SNPs was rs3087918, rs11160608 and rs7158663.

Table 5. Haplotype analysis of MEG3 rs3087918.

Haplotypes	Control (%)	Case (%)	OR (95%)	P
TAG	293(41.89)	155(37.44)	reference	-
GCG	206(29.89)	105(25.36)	0.96(0.71-1.31)	0.811
TAA	94(13.89)	67(16.18)	1.35(0.93-1.95)	0.113
GCA	57(8.89)	33(7.97)	1.09(0.68-1.75)	0.707
TCG	21(3.89)	33(7.97)	2.97 (1.66-5.31)	<0.001*

*The *P* Value < 0.05.

The order of the three SNPs was rs3087918, rs11160608 rs7158663. Haplotypes with frequency less than 0.03 were excluded. OR: odds ratio; CI: confidence interval.

The function prediction of the rs3087918 in MEG3

We used RNAfold (http://rna.tbi.univie.ac.at//cgi-bin/RNAWebSuite/RNAfold.cgi) and LncRNASNP2 (http://bioinfo.life.hust.edu.cn/lncRNASNP/) database to predict the potential function of rs3078918. The centroid secondary structure of rs3087918 was shown in *Figure 1*, we learned that mutant allele “G” would significantly change the centroid secondary structure of MEG3. Moreover, its minimum free energy was change from -28.87 kcal to -26.90 kcal/mol, which suggests rs3087918 may increase the structural stability of MEG3. The results of LncRNASNP2 indicated that rs3087918 may gain the targets of hsa-miR-1203 to MEG3 (lncRNA ID: NONHSAT039760.2), while loss the target of hsa-miR-139-3p and hsa-miR-5091 to MEG3 (See *Supplemental Table S4* and Figure *S1*).

Discussion

The occurrence of breast cancer is a result of a long-term complex interaction between individual genetic background and environmental exposure factors. As the most common type of genetic mutation, SNP is of great significance for breast cancer risk, diagnosis, individualized treatment and prognosis prediction. This study is aimed to investigate the association between MEG3 polymorphisms (rs3087918, rs11160608 rs7158663) and breast cancer. Our study recruited 1134 subjects containing 434 breast cancer patients and 700 healthy controls. The results indicated that the mutant homozygous GG of rs3087918 may associated with a decreased risk of BC, especially in females age <= 49. Comparison between case groups showed genotype GG and TG/GG of rs3087918 were correlated with her-2 receptor expression. The results of haplotype analysis for MEG3 showed that compared with wild haploid TAG, TCG haplotype may increase the risk of breast cancer, while other haplotypes were not significantly correlated with breast cancer risk. Furthermore, we found rs3087918 may influence the secondary structure of MEG3 and affect the bind of MEG3 to some miRNAs.

Previous evidences showed that MEG3 was highly expressed in normal tissues such as brain, pituitary, placenta and adrenal gland, and its transcripts can be detected in several human organs including ovary, testes, spleen, pancreas, liver, and mammary gland [7]. However, the expression of MEG3 was lower in various human tumors compared with that in normal human tissues, including breast cancer [24]. MEG3 was recognized as a tumor suppressor deponed on recent researches. *In vitro* experiments showed that restoring the expression of MEG3 could inhibit cancer cells proliferation and induce their apoptosis [25], and a similar tumor inhibition effect was found in nude mice [16]. MEG3 can also participate in epigenetic regulation of transcripts in the MEG3 region, such as DNA methylation [26, 27], snoRNA/microRNA regulation [28-31]. It is also reported that SNPs in MEG3 gene have an influence on cancer risk. For example, Hou et al. observed a statistically significant increased risk between MEG3 rs11160608 and oral squamous cell carcinoma (OSCC) [24]. And Bayarmaa et al. found MEG3 polymorphisms were related to the chemotherapy response and toxicity of paclitaxel and cisplatin in breast cancer patients [32]. Moreover, Yang et al found MEG3 rs7158663 have no association with lung cancer, while MEG3 rs4081134 was significantly influence the susceptibility of lung cancer in the Chinese population [33]. In this study, we found MEG3 rs3087918 was associated with a decreased breast cancer risk. We use a database named LncRNASNP2 (http://bioinfo.life.hust.edu.cn/lncRNASNP/) to predict the potential function of rs3087918 on MEG3 gene. The results indicated that rs3087918 may influence MEG3 binding to miRNAs. In detail, rs3087918 may gain the targets of hsa-miR-1203 to MEG3, while loss the target of hsa-miR-139-3p and hsa-miR-5091 to MEG3. A study performed by Tomoyuki Okumura et al. found has-miR-1203 significantly associated with tumor recurrence [34]. Downregulation of has-miR-139-3p could induce cancer cell migration and invasion [35-37], and a pooled analysis proved that high has-miR-139-3p expression was related to a better prognosis for hepatocellular carcinoma [38]. Thus, has-miR-139-3p was attributed as a tumor suppressor [39]. Hsa-miR-5091 was also reported as a biomarker with better prognosis for pancreatic ductal adenocarcinoma [40]. These were coincident with our results that rs3087918 was related to a decreased risk of breast cancer.

To be best of our knowledge, this is the first study to explore the association between MEG3 SNPs (rs3087918, rs11160608 rs7158663) and breast cancer risk. However, there are some potential limitations need to be clarified. First, we failed to consider the potential influence of environmental, lifestyle and other unknow risk factors on our study. Secondly, this is a one center case-control study with a small sample scale, we should not ignore the selective bias. In the future, more complete and larger sample scale study need to accomplish.

Conclusion

The wild-type homozygous GG of MEG3 rs3087918 was associated with a decreased risk of breast cancer. MEG3 haplotype TCG may increase the risk of breast cancer and it may owe to its effect on the structure and function of MEG3.

List Of Abbreviations

BC: Breast cancer; MEG3: Maternally expressed gene 3; lncRNA: long non-coding RNA; MAF: minor allele frequency; HWE: Hardy–Weinberg Equilibrium; BMI: body mass index; ORs: odds ratios; CIs: 95% confidence intervals;

Declarations

Ethics approval and consent to participate

The protocol of this study was approved by the Ethics Committee of the Second Affiliated Hospital of Xi'an Jiaotong University Shaanxi Province (Xi'an, China). All patients gave written informed consent prior to participation in the study.

Consent for publication

Not applicable.

Availability of data and materials

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests

We declare no conflicts of interest for this study.

Funding

Not applicable.

Authors' contributions

LK, ZYY, ZZ, and WY collected the samples. WSQ, XP, DYJ, LS, and LN detected the SNPs. DZJ and ZGX guided experiments. ZY and WM analyzed and interpreted the data. ZY was a major contributor in writing the manuscript. All authors read and approved the final manuscript.

Acknowledgements

We thank all members of our study team for their whole-hearted cooperation and all included participants for their wonderful cooperation.

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A: **Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries**. *CA Cancer J Clin* 2018, **68**(6):394-424.

2. Lehrer S, Green S, Rosenzweig KE: **Affluence and Breast Cancer**. *The breast journal* 2016, **22**(5):564-567.
3. Veronesi U, Boyle P, Goldhirsch A, Orecchia R, Viale G: **Breast cancer**. *Lancet (London, England)* 2005, **365**(9472):1727-1741.
4. Gray JM, Rasanayagam S, Engel C, Rizzo J: **State of the evidence 2017: an update on the connection between breast cancer and the environment**. *Environmental health : a global access science source* 2017, **16**(1):94.
5. Rodgers KM, Udesky JO, Rudel RA, Brody JG: **Environmental chemicals and breast cancer: An updated review of epidemiological literature informed by biological mechanisms**. *Environmental research* 2018, **160**:152-182.
6. Miyoshi N, Wagatsuma H, Wakana S, Shiroishi T, Nomura M, Aisaka K, Kohda T, Surani MA, Kaneko-Ishino T, Ishino F: **Identification of an imprinted gene, Meg3/Gtl2 and its human homologue MEG3, first mapped on mouse distal chromosome 12 and human chromosome 14q**. *Genes to cells : devoted to molecular & cellular mechanisms* 2000, **5**(3):211-220.
7. Zhou Y, Zhang X, Klibanski A: **MEG3 noncoding RNA: a tumor suppressor**. *Journal of molecular endocrinology* 2012, **48**(3):R45-53.
8. da Rocha ST, Edwards CA, Ito M, Ogata T, Ferguson-Smith AC: **Genomic imprinting at the mammalian Dlk1-Dio3 domain**. *Trends in genetics : TIG* 2008, **24**(6):306-316.
9. Zhang X, Rice K, Wang Y, Chen W, Zhong Y, Nakayama Y, Zhou Y, Klibanski A: **Maternally expressed gene 3 (MEG3) noncoding ribonucleic acid: isoform structure, expression, and functions**. *Endocrinology* 2010, **151**(3):939-947.
10. Wei GH, Wang X: **lncRNA MEG3 inhibit proliferation and metastasis of gastric cancer via p53 signaling pathway**. *European review for medical and pharmacological sciences* 2017, **21**(17):3850-3856.
11. Zhang J, Yao T, Wang Y, Yu J, Liu Y, Lin Z: **Long noncoding RNA MEG3 is downregulated in cervical cancer and affects cell proliferation and apoptosis by regulating miR-21**. *Cancer biology & therapy* 2016, **17**(1):104-113.
12. Sun L, Li Y, Yang B: **Downregulated long non-coding RNA MEG3 in breast cancer regulates proliferation, migration and invasion by depending on p53's transcriptional activity**. *Biochemical and biophysical research communications* 2016, **478**(1):323-329.
13. He Y, Luo Y, Liang B, Ye L, Lu G, He W: **Potential applications of MEG3 in cancer diagnosis and prognosis**. *Oncotarget* 2017, **8**(42):73282-73295.
14. Li J, Zi Y, Wang W, Li Y: **Long Noncoding RNA MEG3 Inhibits Cell Proliferation and Metastasis in Chronic Myeloid Leukemia via Targeting miR-184**. *Oncology research* 2018, **26**(2):297-305.
15. Zhang W, Shi S, Jiang J, Li X, Lu H, Ren F: **LncRNA MEG3 inhibits cell epithelial-mesenchymal transition by sponging miR-421 targeting E-cadherin in breast cancer**. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie* 2017, **91**:312-319.

16. Zhuo H, Tang J, Lin Z, Jiang R, Zhang X, Ji J, Wang P, Sun B: **The aberrant expression of MEG3 regulated by UHRF1 predicts the prognosis of hepatocellular carcinoma**. *Molecular carcinogenesis* 2016, **55**(2):209-219.
17. Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, Marchini JL, McCarthy S, McVean GA, Abecasis GR: **A global reference for human genetic variation**. *Nature* 2015, **526**(7571):68-74.
18. Michailidou K, Beesley J, Lindstrom S, Canisius S, Dennis J, Lush MJ, Maranian MJ, Bolla MK, Wang Q, Shah M *et al*: **Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer**. *Nature genetics* 2015, **47**(4):373-380.
19. Pellegrino B, Bella M, Michiara M, Zanelli P, Naldi N, Porzio R, Bortesi B, Boggiani D, Zanoni D, Camisa R *et al*: **Triple negative status and BRCA mutations in contralateral breast cancer: a population-based study**. *Acta bio-medica : Atenei Parmensis* 2016, **87**(1):54-63.
20. Goovaerts T, Steyaert S, Vandenbussche CA, Galle J, Thas O, Van Criekinge W, De Meyer T: **A comprehensive overview of genomic imprinting in breast and its deregulation in cancer**. *Nature communications* 2018, **9**(1):4120.
21. Cao X, Zhuang S, Hu Y, Xi L, Deng L, Sheng H, Shen W: **Associations between polymorphisms of long non-coding RNA MEG3 and risk of colorectal cancer in Chinese**. *Oncotarget* 2016, **7**(14):19054-19059.
22. Zhuo ZJ, Zhang R, Zhang J, Zhu J, Yang T, Zou Y, He J, Xia H: **Associations between lncRNA MEG3 polymorphisms and neuroblastoma risk in Chinese children**. *Aging* 2018, **10**(3):481-491.
23. Miao YR, Liu W, Zhang Q, Guo AY: **lncRNASNP2: an updated database of functional SNPs and mutations in human and mouse lncRNAs**. *Nucleic acids research* 2018, **46**(D1):D276-D280.
24. Hou Y, Zhang B, Miao L, Ji Y, Yu Y, Zhu L, Ma H, Yuan H: **Association of long non-coding RNA MEG3 polymorphisms with oral squamous cell carcinoma risk**. *Oral diseases* 2019, **25**(5):1318-1324.
25. Xiu YL, Sun KX, Chen X, Chen S, Zhao Y, Guo QG, Zong ZH: **Upregulation of the lncRNA Meg3 induces autophagy to inhibit tumorigenesis and progression of epithelial ovarian carcinoma by regulating activity of ATG3**. *Oncotarget* 2017, **8**(19):31714-31725.
26. Zhao J, Dahle D, Zhou Y, Zhang X, Klibanski A: **Hypermethylation of the promoter region is associated with the loss of MEG3 gene expression in human pituitary tumors**. *The Journal of clinical endocrinology and metabolism* 2005, **90**(4):2179-2186.
27. Benetatos L, Dasoula A, Hatzimichael E, Georgiou I, Syrrou M, Bourantas KL: **Promoter hypermethylation of the MEG3 (DLK1/MEG3) imprinted gene in multiple myeloma**. *Clinical lymphoma & myeloma* 2008, **8**(3):171-175.
28. Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, Alder H, Liu CG, Oue N, Yasui W *et al*: **Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis**. *The Lancet Oncology* 2010, **11**(2):136-146.
29. Shih KK, Qin LX, Tanner EJ, Zhou Q, Bisogna M, Dao F, Olvera N, Viale A, Barakat RR, Levine DA: **A microRNA survival signature (MiSS) for advanced ovarian cancer**. *Gynecologic oncology* 2011, **121**(3):444-450.

30. Sahoo T, del Gaudio D, German JR, Shinawi M, Peters SU, Person RE, Garnica A, Cheung SW, Beaudet AL: **Prader-Willi phenotype caused by paternal deficiency for the HBII-85 C/D box small nucleolar RNA cluster**. *Nature genetics* 2008, **40**(6):719-721.
31. Bortolin-Cavaille ML, Cavaille J: **The SNORD115 (H/MBII-52) and SNORD116 (H/MBII-85) gene clusters at the imprinted Prader-Willi locus generate canonical box C/D snoRNAs**. *Nucleic acids research* 2012, **40**(14):6800-6807.
32. Bayarmaa B, Wu Z, Peng J, Wang Y, Xu S, Yan T, Yin W, Lu J, Zhou L: **Association of LncRNA MEG3 polymorphisms with efficacy of neoadjuvant chemotherapy in breast cancer**. *BMC cancer* 2019, **19**(1):877.
33. Yang Z, Li H, Li J, Lv X, Gao M, Bi Y, Zhang Z, Wang S, Li S, Li N *et al*: **Association Between Long Noncoding RNA MEG3 Polymorphisms and Lung Cancer Susceptibility in Chinese Northeast Population**. *DNA and cell biology* 2018, **37**(10):812-820.
34. Okumura T, Shimada Y, Omura T, Hirano K, Nagata T, Tsukada K: **MicroRNA profiles to predict postoperative prognosis in patients with small cell carcinoma of the esophagus**. *Anticancer research* 2015, **35**(2):719-727.
35. Yonemori M, Seki N, Yoshino H, Matsushita R, Miyamoto K, Nakagawa M, Enokida H: **Dual tumor-suppressors miR-139-5p and miR-139-3p targeting matrix metalloprotease 11 in bladder cancer**. *Cancer science* 2016, **107**(9):1233-1242.
36. Ng L, Wan TM, Man JH, Chow AK, Iyer D, Chen G, Yau TC, Lo OS, Foo DC, Poon JT *et al*: **Identification of serum miR-139-3p as a non-invasive biomarker for colorectal cancer**. *Oncotarget* 2017, **8**(16):27393-27400.
37. Sannigrahi MK, Sharma R, Singh V, Panda NK, Rattan V, Khullar M: **Role of Host miRNA Hsa-miR-139-3p in HPV-16-Induced Carcinomas**. *Clinical cancer research : an official journal of the American Association for Cancer Research* 2017, **23**(14):3884-3895.
38. Zhu Y, Zhou C, He Q: **High miR-139-3p expression predicts a better prognosis for hepatocellular carcinoma: a pooled analysis**. *The Journal of international medical research* 2019, **47**(1):383-390.
39. Zhang W, Xu J, Wang K, Tang X, He J: **miR-139-3p suppresses the invasion and migration properties of breast cancer cells by targeting RAB1A**. *Oncology reports* 2019, **42**(5):1699-1708.
40. Liao X, Wang X, Huang K, Yang C, Yu T, Han C, Zhu G, Su H, Huang R, Peng T: **Genome-scale analysis to identify prognostic microRNA biomarkers in patients with early stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy**. *Cancer management and research* 2018, **10**:2537-2551.

Additional Files

Figure S1. The prediction results of s3087918 affect the bind of MEG3 to miRNAs. (A) rs3087918 caused has-miR1203 target gain; (B) rs3087918 caused has-miR-139-3p target loss; (C) rs3087918 caused has-miR-5091 target loss.

Table S1. Primers used for this study.

Table S2. Stratified Analysis of rs11160608 and rs7158663 by age, BMI and menopausal status.

Table S3. Association analysis between three SNPs inMEG3 and Molecular typing of breast cancer.

Table S4. Rs3087918 influence MEG3 binding to miRNAs based on LncRNASNP2 database.

Figures



Figure 1

The RNAfold algorithm in silico predicting the impact of rs3087918. MFE: minimum free energy.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Supplementalattachments.pdf